🔎 Trials Near Me

Domov › Sladkorna bolezen tipa 2 › Pennsylvania

Klinične študije za Sladkorna bolezen tipa 2 v Pennsylvania

30 študij za Sladkorna bolezen tipa 2 išče udeležence na lokacijah v Pennsylvania.

Mesta v Pennsylvania

Uradno besedilo študije (angleško)

A Study of Clazakizumab (LY5724886) in Adults With Elevated hsCRP and at Increased Risk for Cardiovascular Event

  • Suburban Research Associates, West Chester
  • Cardiology Consultants of Philadelphia Yardley, Yardley
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07783802

A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight

  • Heritage Valley Medical Group, Beaver
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07564414

EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease

  • Heritage Valley Medical Group, Beaver
  • Capital Area Research, LLC, Camp Hill
  • Thomas Jefferson University, Philadelphia
  • in še 8
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07064473

A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

  • Heritage Valley Medical Group, Beaver
  • Preferred Primary Care Physicians-Pittsburgh-63932, Pittsburgh
  • Preferred Primary Care Physicians, Pittsburgh
  • in še 1
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 30. sep. 2026 · NCT07754461

A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

  • Capital Area Research, Camp Hill
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 55 in več · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT06112418

A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes

  • Preferred Primary Care Physicians, Preferred Clinical Research-St. Clair, Pittsburgh
  • Preferred Primary Care Physicians, Uniontown
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07282600

A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight

  • Research Site, Scottdale
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT07784270

Phenotyping Genetic Risk for Type 2 Diabetes

  • Childrens Hospital of Philadelphia, Philadelphia
  • University of Pennsylvania, Philadelphia
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 10–70 · Vsi spoli · Posodobljeno 21. sep. 2026 · NCT04024631

A Study of Once-daily Oral ASC30 to Evaluate the Efficacy and Safety in Adult Participants With Obesity or Overweight With Type 2 Diabetes

  • AURORA-2 Clinical Site, Philadelphia
  • AURORA-2 Clinical Site, Pittsburgh
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT07743450

A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes

  • VA Pittsburgh Healthcare System, Pittsburgh
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT07351058

A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide

  • Frontier Clinical Research, LLC, Scottdale
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT06897475

Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease

  • Northeast Clinical Research Center, Bethlehem
  • Suburban Research Associates, West Chester
Vključevanje udeležencevFaza 2
Starost 18–80 · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT07271186

A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

  • Preferred Primary Care Physicians, Inc., Uniontown
Vključevanje udeležencevFaza 2
Starost 18–75 · Vsi spoli · Posodobljeno 11. sep. 2026 · NCT07668388

A Study to Find Out if the Study Drug Elecoglipron Helps Adults With Type 2 Diabetes Mellitus by Comparing it With Semaglutide, a Medicine Already Used to Treat Type 2 Diabetes Mellitus

  • Research Site, Feasterville-Trevose
  • Research Site, Philadelphia
Vključevanje udeležencevFaza 3
Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07662213

Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D)

  • Suburban Research Associates, West Chester
Vključevanje udeležencevFaza 2
Starost 18 in več · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07296484

A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in Children and Adolescents With Type 2 Diabetes

  • Children's Hosptl Philadelphia, Philadelphia
Vključevanje udeležencevFaza 3
Starost 10–18 · Vsi spoli · Posodobljeno 9. sep. 2026 · NCT07282613

A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS)

  • Children's Hospital of Philadelphia, Philadelphia
  • St Christophers Hospital For Children, Philadelphia
Vključevanje udeležencevFaza 3
Starost 10–17 · Vsi spoli · Posodobljeno 7. avg. 2026 · NCT06739122

The GRoceries Aimed at Increasing Nutrition Study

  • University of Pennsylvania, Philadelphia
Vključevanje udeležencevOmenja plačilo za udeležence
Starost 45–70 · Vsi spoli · Posodobljeno 6. avg. 2026 · NCT07167004

Pharmacogenetics of Response to GLP1R Agonists

  • Amish Research Clinic, Lancaster
Vključevanje udeležencevFaza 1Vabljeni zdravi prostovoljci
Starost 18–89 · Vsi spoli · Posodobljeno 27. jul. 2026 · NCT05071898

CGM for Management of Type 2 Diabetes in Pregnancy

  • University of Pennsylvania, Philadelphia
Vključevanje udeležencev
Starost 18–50 · Ženske · Posodobljeno 29. jun. 2026 · NCT06628453

Sleep and Glycemic Control in Type 2 Diabetes Adolescents

  • Children's Hospital of Philadelphia, Philadelphia
Vključevanje udeležencev
Starost 12–20 · Vsi spoli · Posodobljeno 29. jun. 2026 · NCT04213547

DISCOVERY of Risk Factors for Type 2 Diabetes in Youth

  • Children's Hospital of Philadelphia, Philadelphia
Vključevanje udeležencevOpazovalna študija
Starost 8–15 · Vsi spoli · Posodobljeno 7. maj 2026 · NCT06525259

Pilot-Testing Strategies to Improve Outcomes for Youth With Type 2 Diabetes by Addressing Health-Related Social Needs

  • UPMC Children's Hospital of Pittsburgh, Pittsburgh
Vključevanje udeležencevVabljeni zdravi prostovoljci
Starost 13 in več · Vsi spoli · Posodobljeno 27. apr. 2026 · NCT07216118

Transformative Research in Diabetic Nephropathy 2.0

  • Penn Presbyterian Medical Center, Philadelphia
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 18 in več · Vsi spoli · Posodobljeno 2. mar. 2026 · NCT07444203

Pilot-Testing Real-Time Engagement for Learning to Effectively Control Type 2 Diabetes

  • Children's Hospital of Pittsburgh, Pittsburgh
Vključevanje udeležencev
Starost 16–24 · Vsi spoli · Posodobljeno 20. feb. 2026 · NCT07270016

Brain Health in Youth With Normal Weight, Overweight and Obesity at Risk for Type 2 Diabetes (T2D)

  • UPMC Children's Hospital of Pittsburgh, Pittsburgh
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
Starost 12–17 · Vsi spoli · Posodobljeno 18. dec. 2025 · NCT05277558

CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes

  • Thomas Jefferson University, Philadelphia
Vključevanje udeležencev
Starost 18 in več · Ženske · Posodobljeno 14. okt. 2025 · NCT07184775

Impact of a Diabetes Education Mobile Web Application on Patients With Uncontrolled Type 2 Diabetes

  • Reading Hospital, an affiliate of Tower Health, West Reading
Vključevanje udeležencev
Starost 18 in več · Vsi spoli · Posodobljeno 30. jul. 2025 · NCT05893927

Vir: ClinicalTrials.gov, podatki pridobljeni 5. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.